La Jolla Pharmaceutical (LJPC) Director Sells $323,200.00 in Stock

La Jolla Pharmaceutical (NASDAQ:LJPC) Director Laura L. Douglass sold 10,000 shares of the stock in a transaction dated Saturday, December 29th. The stock was sold at an average price of $32.32, for a total transaction of $323,200.00. Following the completion of the transaction, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $193,920. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of La Jolla Pharmaceutical (LJPC) opened at $30.03 on Friday. La Jolla Pharmaceutical has a 52 week low of $16.71 and a 52 week high of $39.28.

La Jolla Pharmaceutical (NASDAQ:LJPC) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.19) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.24) by $0.05. equities research analysts forecast that La Jolla Pharmaceutical will post -4.91 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the business. Legal & General Group Plc boosted its stake in La Jolla Pharmaceutical by 11.6% in the second quarter. Legal & General Group Plc now owns 4,456 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 462 shares during the last quarter. Jane Street Group LLC bought a new position in La Jolla Pharmaceutical in the third quarter valued at approximately $200,000. Trexquant Investment LP bought a new position in La Jolla Pharmaceutical in the third quarter valued at approximately $217,000. Voya Investment Management LLC bought a new position in La Jolla Pharmaceutical in the second quarter valued at approximately $243,000. Finally, Nationwide Fund Advisors boosted its stake in La Jolla Pharmaceutical by 20.4% in the second quarter. Nationwide Fund Advisors now owns 9,952 shares of the biopharmaceutical company’s stock valued at $296,000 after acquiring an additional 1,688 shares during the last quarter.

LJPC has been the subject of several recent research reports. JPMorgan Chase & Co. lowered shares of La Jolla Pharmaceutical from an “overweight” rating to an “underweight” rating and set a $20.00 price target for the company. in a research report on Friday, December 8th. HC Wainwright upped their price objective on shares of La Jolla Pharmaceutical from $62.00 to $91.00 and gave the stock a “buy” rating in a research note on Friday, December 29th. BidaskClub cut shares of La Jolla Pharmaceutical from a “sell” rating to a “strong sell” rating in a research note on Friday, December 15th. Zacks Investment Research raised shares of La Jolla Pharmaceutical from a “hold” rating to a “buy” rating and set a $39.00 price objective on the stock in a research note on Wednesday, November 1st. Finally, SunTrust Banks reaffirmed a “buy” rating and set a $65.00 price objective (down from $67.00) on shares of La Jolla Pharmaceutical in a research note on Friday, December 22nd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $57.14.

COPYRIGHT VIOLATION NOTICE: “La Jolla Pharmaceutical (LJPC) Director Sells $323,200.00 in Stock” was reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/01/06/la-jolla-pharmaceutical-ljpc-director-sells-323200-00-in-stock.html.

La Jolla Pharmaceutical Company Profile

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Insider Buying and Selling by Quarter for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit